Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05528848 · ClinicalTrials.gov registry record · Phase 1

Multi-System Analysis of Opioid Receptor Binding

A Phase 1 study of Healthy and Opioid Use Disorder, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT05528848: Recruiting Phase 1 study of Healthy and Opioid Use Disorder, sponsored by University of Pennsylvania.

NCT05528848 is a Phase 1 study of Healthy and Opioid Use Disorder that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 60 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05528848, a Phase 1 study of Healthy and Opioid Use Disorder, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study will enroll up to 60 adults (including 30 females and 30 males) in three cohorts of up to 20 subjects each. In all three groups, \[11C\]carfentanil whole-body PET imaging will be used to examine the central nervous system (CNS) and broader systemic opioid binding in an initial scan session. In the two groups not receiving standard of care medication assisted treatment (MAT) for opioid use disorder (OUD) the effects on \[11C\]carfentanil binding potential of the blockade of opioid binding by the non-selective opioid antagonist naloxone administered parenterally in a second scan session will also be examined. If two scans are completed they can be done on the same day or on different days.

Primary Outcome

Measure MOR BPND following the administration of \[11C\]carfentanil alone in 5 brain regions of interest (ROIs) relevant to addiction (the subgenual anterior cingulate, ventral pallidum, amygdala, nucleus accumbens, and dorsal striatum), spinal cord (key role in transmitting pain signals) and organs outside the central nervous system (CNS) that contain mu-opioid receptors (e.g., the gastrointestinal tract, heart).

Interventions

  • DRUG Loperamide Hydrochloride
  • DRUG Naloxone
  • DRUG Carfentanil, C-11

Study Locations (1)

Pennsylvania

  • University of Pennsylvania, Perelman School of Medicine - Philadelphia

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-09-20
Est. Completion 2026-09
Phase Phase 1
University of Pennsylvania

1,423 total trials

What NCT05528848 shows while recruiting

NCT05528848 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Loperamide Hydrochloride is the first listed.

NCT05528848 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05528848 about?

NCT05528848 is a clinical study titled "Multi-System Analysis of Opioid Receptor Binding". This study will enroll up to 60 adults (including 30 females and 30 males) in three cohorts of up to 20 subjects each. In all three groups, \[11C\]carfentanil whole-body PET imaging will be used to examine the central nervous system (CNS) and broader systemic opioid binding in an initial scan sessio...

What is the current status of trial NCT05528848?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-09-20. Estimated completion is 2026-09.

What conditions does trial NCT05528848 study?

This clinical trial studies the following conditions: Healthy, Opioid Use Disorder.

What interventions are being tested in trial NCT05528848?

The interventions under investigation include: Loperamide Hydrochloride (DRUG), Naloxone (DRUG), Carfentanil, C-11 (DRUG).

Who is sponsoring clinical trial NCT05528848?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05528848 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05528848's enrollment target sits among peer trials

60 369th of 1090 higher than 689 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05528848, the US trial registry maintained by the National Library of Medicine. NCT05528848 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.